- Home
- UAN vs NEO Comparison
UAN vs NEO Comparison
Compare UAN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- NEO
- Stock Information
- Founded
- UAN 2007
- NEO 2001
- Country
- UAN United States
- NEO United States
- Employees
- UAN N/A
- NEO N/A
- Industry
- UAN Agricultural Chemicals
- NEO Precision Instruments
- Sector
- UAN Industrials
- NEO Health Care
- Exchange
- UAN Nasdaq
- NEO Nasdaq
- Market Cap
- UAN 918.1M
- NEO 902.1M
- IPO Year
- UAN 2011
- NEO 1999
- Fundamental
- Price
- UAN $88.93
- NEO $7.53
- Analyst Decision
- UAN
- NEO Buy
- Analyst Count
- UAN 0
- NEO 9
- Target Price
- UAN N/A
- NEO $13.31
- AVG Volume (30 Days)
- UAN 22.2K
- NEO 2.2M
- Earning Date
- UAN 07-28-2025
- NEO 07-29-2025
- Dividend Yield
- UAN 7.60%
- NEO N/A
- EPS Growth
- UAN N/A
- NEO N/A
- EPS
- UAN 7.13
- NEO N/A
- Revenue
- UAN $540,525,000.00
- NEO $672,361,000.00
- Revenue This Year
- UAN N/A
- NEO $13.97
- Revenue Next Year
- UAN N/A
- NEO $11.36
- P/E Ratio
- UAN $12.47
- NEO N/A
- Revenue Growth
- UAN N/A
- NEO 10.10
- 52 Week Low
- UAN $62.94
- NEO $6.08
- 52 Week High
- UAN $93.73
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- UAN 64.97
- NEO 52.96
- Support Level
- UAN $88.08
- NEO $7.04
- Resistance Level
- UAN $90.24
- NEO $7.73
- Average True Range (ATR)
- UAN 2.58
- NEO 0.35
- MACD
- UAN -0.12
- NEO 0.08
- Stochastic Oscillator
- UAN 58.87
- NEO 79.78
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.